Journal of the American Chemical Society · 2023 · 56 citations · 32 references
Life SciencesCell BiologyMolecular BiologyAntibody EngineeringCell SignalingProtein EngineeringCargo SortingLysosomal DegradationMembrane ProteinsProtein DegradationProtein SortingProtein TargetingAntibodiesEndolysosomal SortingLysosomal Cargo DegradationLysosomal Degradation PathwaysLysosomal Membrane ProteinsMannose 6-Phosphate ReceptorsSignal PeptidesTargeted Protein Degradation
Membrane proteins are a crucial class of therapeutic targets that remain challenging to modulate using traditional occupancy-driven inhibition strategies or current proteolysis-targeting degradation approaches. Here, we report that the inherent endolysosomal sorting machinery can be harnessed for the targeted degradation of membrane proteins. A new degradation technique, termed signal-mediated lysosome-targeting chimeras (SignalTACs), was developed by genetically fusing the signaling motif from the cation-independent mannose-6-phosphate receptor (CI-M6PR) to a membrane protein binder. Antibody-based SignalTACs were constructed with the CI-M6PR signal peptides fused to the C-terminus of both heavy and light chains of IgG. We demonstrated the scope of this platform technology by degrading five pathogenesis-related membrane proteins, including HER2, EGFR, PD-L1, CD20, and CD71. Furthermore, two simplified constructs of SignalTACs, nanobody-based and peptide-based SignalTACs, were created and shown to promote the lysosomal degradation of target membrane proteins. Compared to the parent antibodies, SignalTACs exhibited significantly higher efficiency in inhibiting tumor cell growth both in vitro and in vivo. This work provides a simple, general, and robust strategy for degrading membrane proteins with molecular precision and may represent a powerful platform with broad research and therapeutic applications.
32
Kathleen M. Sakamoto, Kyung B. Kim, Akiko Kumagai et al. · Proceedings of the National Academy of Sciences · 2001 · 2.5K citations · Full text
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +17
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Hyun‐Soo Cho, Karen Mason, Kasra X. Ramyar et al. · Nature · 2003 · 1.6K citations
Lysosome-targeting chimaeras for degradation of extracellular proteins
Steven M. Banik, Kayvon Pedram, Simon Wisnovsky et al. · Nature · 2020 · 1.1K citations · Full text